Thursday, Nov. 11, 2021
*Dates, times and program schedule subject to change.
The understanding of cancer immunobiology has increased dramatically in recent years, leading to the successful development of novel immune-based treatment options to improve cancer patient outcomes. The SITC Primer on Tumor Immunology and Cancer Immunotherapy™ is designed to provide a foundation for understanding core immunology principles as they relate to basic and clinical research in immunotherapy of cancer. This year, the Primer on Tumor Immunology and Cancer Immunotherapy™ will also touch on emerging therapies and technologies to ensure attendees at all levels stay updated in our expanding field, while also laying a comprehensive foundational base for all SITC attendees.
While immunotherapy treatments, particularly anti-PD-1 therapies, have improved outcomes for some patients, the issue of post-treatment relapse remains a large problem. The proper choice of treatment after relapse on checkpoint inhibition is therefore a critical issue to solve. This symposium will explore the preclinical and clinical data on sequencing of immunotherapies, in order to improve patient outcomes and ensure the field of immunotherapy remains at the forefront of oncology care.
This two-hour program features two parts. The first part will open with an overview of the grant submission process, briefly outlining funding opportunities and how to navigate those. Part one will also address critical points of government and private sector grant submissions. The second part will consist of a “mini-study section,” allowing attendees to experience how a study section evaluates a grant proposal, which will help attendees identify points that determine the success or failure of a grant proposal and help them optimize the process of grant re-submission.